Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma (NCT05535166)
SJiMB21: Phase 2 Study of Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma
🩺 Plain-English Summary (8th-Grade Level)
This is a multi-center, multinational phase 2 trial that aims to explore the use of molecular and clinical risk-directed therapy in treatment of children 0-4.99 years of age with newly diagnosed medulloblastoma.
Who can join: Review the eligibility criteria below.
Location: Lucille Packard Children's Hospital Stanford — Palo Alto, California
Age range: Not specified to 59 Months
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (10 Sites)
- Lucille Packard Children's Hospital Stanford — Palo Alto, California
- Orlando Health Arnold Palmer Hospital for Children — Orlando, Florida
- St. Joseph's Children's Hospital — Tampa, Florida
- C.S. MOTT Children's Hospital, University of Michigan — Ann Arbor, Michigan
- Children's Hospital and Clinics of Minnesota — Minneapolis, Minnesota
- St. Jude Children's Research Hospital — Memphis, Tennessee
- UT Southwestern Medical Center/Harold C Simmons Comprehensive Cancer Center — Dallas, Texas
- Cook Children's Medical Center — Fort Worth, Texas
- Texas Children's Hospital — Houston, Texas
- Primary Children's Hospital — Salt Lake City, Utah
📞 Contact the Study Coordinator
Phone: (901) 595-2544
Email: tabatha.doyle@stjude.org
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Medulloblastoma
- Reduced Craniospinal Radiation Therapy and Chemotherapy in Treating Younger Patients With Newly Diagnosed WNT-Driven Medulloblastoma — Birmingham, Alabama
- A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma — Palo Alto, California
- A Pilot Study of SurVaxM in Children Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma — Los Angeles, California
- HeadStart4: Newly Diagnosed Children (<10 y/o) With Medulloblastoma and Other CNS Embryonal Tumors — Birmingham, Alabama
- Comparison of Neurocognitive Outcome in Two Standard Regimen for Treatment of Low-risk Medulloblastoma — Birmingham, Alabama
- Liothyronine in Combination With BIT Regimen for Medulloblastoma With or Without Minimal Residual Disease — San Francisco, California
Explore by condition: All Medulloblastoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.